Vanguard disaggregates holdings; Bio‑Rad Labs (NYSE: BIO) shows 0 shares
Rhea-AI Filing Summary
The Vanguard Group filed an amended Schedule 13G reporting that it currently beneficially owns 0 shares (0%) of Bio-Rad Laboratories Inc. The filing explains that on January 12, 2026 Vanguard completed an internal realignment and began reporting certain subsidiaries' holdings separately, in accordance with SEC Release No. 34-39538 (January 12, 1998). The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did The Vanguard Group report for BIO in this Schedule 13G/A?
The Vanguard Group reported 0 shares (0%) beneficially owned of Bio-Rad Laboratories Inc. The amendment lists voting and dispositive powers as 0 across sole and shared categories.
Why did Vanguard file an amendment to its 13G for Bio-Rad (BIO)?
Vanguard states it completed an internal realignment on January 12, 2026, and certain subsidiaries now report holdings separately. This disaggregation is made under SEC Release No. 34-39538 (January 12, 1998).
Who signed the Schedule 13G/A amendment for BIO?
The amendment is signed by Ashley Grim, Head of Global Fund Administration, and dated 03/26/2026, as the authorized representative for The Vanguard Group.
Does the filing indicate any third party holds more than 5% of BIO?
The filing states that no other person's interest in the securities reported is more than 5%, and The Vanguard Group lists ownership as 5 percent or less of a class where applicable.